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Despite successful antiretroviral therapy (ART), low-level viremia (LLV) may be intermittently detected in
most HIV-infected patients. Longitudinal blood plasma and resting CD4 T cells were obtained from two
patients on suppressive ART to investigate the source of LLV. Single-genome sequencing of HIV-1 env from
LLV plasma was performed, and the sequences were compared to sequences recovered from limiting-dilution
outgrowth assays of resting CD4 T cells. The circulating LLV virus clone was identical to virus recovered from
outgrowth assays from pools of millions of resting CD4 T cells. Understanding the sources of LLV requires
evaluation of all possible reservoirs of persistent HIV infection.
Antiretroviral therapy (ART) reduces the level of plasma
HIV-1 RNA to below the detection limit of clinical assays
(50 copies/ml). However, approximately 75% of patients are
found to have stable, persistent low-level viremia (LLV) when
tested with more sensitive methods (12, 14, 18, 21, 23). Al-
though such patients remain clinically stable on ART, persis-
tent virus expression may contribute to long-term complica-
tions (11), and the cellular source of LLV poses a significant
challenge to future attempts to induce a drug-free remission of
HIV disease and eradication of infection (25).
The source(s) of LLV is unclear and controversial (10, 19).
Latent, persistent infection of resting CD4 T cells is well
described (5), and induction of viral replication in this substan-
tial reservoir of infection might produce LLV in some or all
patients. However, cellular sources outside the resting CD4 T
cell pool have been postulated. Macrophages can survive and
produce virus for long periods of time in cell culture (20).
Hematopoietic progenitor cells may be infected by HIV (7),
although this is also disputed (33). Other persistent, durable
cellular reservoirs may exist.
Bailey et al. carried out an extensive study of sequences
found in patients with LLV (4). In five of nine patients, LLV
was populated with a predominant viral clone. This viral clone
was found to be underrepresented in DNA recovered from
circulating resting CD4 T cells and in some cases was also
underrepresented in replication-competent virus recovered
from these cells. The researchers concluded that LLV repre-
sented the production of a small number of viral clones without
evident evolution, possibly by cells other than circulating
CD4 T cells. Herein, we report two cases in which the circu-
lating LLV virus clone, as identified by single-genome sequenc-
ing, was similarly monomorphic but where an identical repli-
cating viral clone was discovered only after analysis of the
replication-competent virus recovered from millions of resting
CD4 T cells cultured in a limiting dilution. While our findings
are complementary to those of Bailey and colleagues, they
highlight the possibility that LLV is derived from virus that
persists and may expand by homeostatic proliferation (8)
within resting CD4 T cells but may be difficult to uncover
without a detailed analysis of the replication-competent sub-
population of provirus harbored by resting CD4 T cells.
Per study protocol, lymphocytes from two patients on sup-
pressive ART were obtained by continuous-flow leukapheresis.
Resting CD4 T cells were isolated, and the frequency of
replication-competent virus was assessed by limiting-dilution
culture (2). Both patients provided written informed consent,
and the study was approved by the University of North Caro-
lina Office of Human Research Ethics Institutional Review
Board. Outgrowth assays found the frequencies of resting cell
infection to be 0.41 to 0.60 per million resting CD4 T cells for
patient 15 and 3.15 to 6.00 per million resting CD4 T cells for
patient 41.
HIV-1 RNA from 7 ml of stored plasma from patient 15 at
a single time point, and 14 ml of plasma from patient 41 at two
time points was isolated as previously described (1, 16, 22, 28).
In parallel, to obtain virus sequences from resting CD4 T
cells, cell-free viral RNA from cell culture supernatants was
extracted. HIV-1 RNA was reverse transcribed to cDNA, and
the env gene was amplified from plasma by using a limiting-
dilution approach and sequenced as previously described (1,
16, 22, 28). If full-length env could not be amplified from
plasma, then nested PCR was performed using V1 (5-TTAT
GGGATCAAAGCCTAAAGCCATGTGTA-3) and V2 (5-
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CTTAATTCCATGTGTACATTGTACTGTGCT-3) prim-
ers. For a subset of the cell culture supernatant-derived full-
length env amplicons for patient 15, a bulk PCR approach of
oligo(dT)-primed cDNA was utilized. A bulk PCR approach
was used to generate all of the cell culture supernatant-derived
amplicons for patient 41.
Longitudinal viral loads for patients 15 and 41 are shown in
Fig. 1. Patient 15 was diagnosed with late-stage HIV-1 infec-
tion with a CD4 T cell count of 38 cells/l. ART was initiated
at that time, resulting in suppression of viremia and mainte-
nance of 50 copies/ml for 40 months prior to enrollment in
an ART intensification clinical trial (2). In contrast to patient
15, patient 41 was diagnosed with acute HIV-1 infection
(Fiebig stage IV) (13) with an indeterminate HIV-1 Western
blot and a CD4 T cell count of 448 cells/l. ART was initiated
approximately 6 months postinfection, resulting in suppression
of viremia and maintenance of 50 copies/ml for several
months prior to enrollment and after completion of an ART
intensification clinical trial (2, 3).
To infer viruses present in resting CD4 T cells, we initially
used single-genome amplification (SGA) to generate 37 full-
length env amplicons from a single cell culture supernatant
derived from a culture of 2.5 million resting CD4 T cells (Fig.
2A). Within the major clade, the 36 sequences were highly
homogeneous (with 19 of 36 sequences completely identical).
Subsequently, a bulk PCR approach was utilized for additional
limiting-dilution culture supernatants, as SGA was not neces-
sary to analyze diversity within the resting cells.
Bulk PCR was used to generate 18 additional env amplicons
(Fig. 2B). For these amplicons, the hypervariable regions V1 to
V5 were sequenced. Thus, a total of 20 env sequences (includ-
ing the SGA-derived major and minor variants identified in
Fig. 2A) were used to measure the diversity within the resting
CD4 T lymphocytes, and these sequences have a maximum
pairwise distance of 5.5%, consistent with a patient who has
chronic HIV-1 infection and has been infected for several years
(29).
Sixteen amplicons were isolated from resting CD4 T lym-
phocytes of patient 41 nearly 5 years after ART initiation. The
resting cell population was extremely homogeneous, with a
mean pairwise genetic distance of 0.22% (Fig. 2C and D), and
the case is analogous to a subject infected with a single variant
sampled during acute infection (1, 16, 28). In addition, four
amplicons were generated by SGA from longitudinal blood
plasma samples separated by a 14-month interval (Fig. 2C and
D) and differ from the resting CD4 T cell population by 2
mutations at most. Thus, a minimal amount of viral diversifi-
cation occurred since initiation of therapy, and this suggests
that viral populations do not diversify in the setting of effective
ART.
To examine the viral diversity of the LLV present within the
blood plasma of patient 15, eight full-length env amplicons and
seven V1-V2 amplicons were generated (Fig. 2B). Two clades
are identified within the phylogenetic tree. The major clade
was highly homogeneous, with 13 of 15 identical sequences and
with one sequence 0.3% divergent from the major clade. In
addition, one sequence was 4.2% divergent from the major
clade. The sequences present in the blood plasma had identi-
cal/nearly identical sequences present in the resting CD4 T
cells. Similarly, identical/nearly identical sequences were ob-
tained from the LLV in the blood plasma and the resting
CD4 T cells from patient 41 (Fig. 2C and D). These results
confirm that the source of ongoing virus production detected in
these patients is the latently infected resting CD4 T cell
population or another cell type infected with a genetically
identical virus and that this virus is primarily clonal in origin.
The twin problems of the persistence of integrated HIV
provirus and chronic low-level viral expression despite effective
ART must be addressed if eradication of HIV infection is to be
achieved. Some mechanisms that contribute to the persistence
of replication-competent HIV DNA genomes within cells are
understood, but the predominant sources of persistent, low-
level expression of virions have not been fully defined.
Some investigators reported that when ART is interrupted,
rebound viremia appears to originate from the CD4 T cell
reservoir (15), but others have found that the source of viral
rebound cannot always be identified (9). Similarly, Bailey et al.
(4) found that the predominant circulating viral species iso-
lated from patients with LLV could not be identified within the
proviral DNA recovered from the resting CD4 T cells in 5 of
9 patients (4).
This study specifically compared the LLV virus to virus ca-
pable of replication that is released after ex vivo activation of
FIG. 1. Longitudinal viral load analyses of patient 15 (A) and pa-
tient 41 (B). Patient 15 was diagnosed with established HIV-1 infection
in December 2003, and ART was promptly initiated. Patient 41 was
diagnosed with acute HIV-1 infection in June 2004 and initiated ART
in December 2004. HIV-1 RNA viral loads determined by Roche
Amplicor assay are shown in black, and those determined by single-
copy assay (SCA) are shown in red (24). Asterisks represent time
points when leukophoresis was performed to obtain virus for resting
cell outgrowth. Daggers represent time points when blood plasma was
assayed by single genome amplification.
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resting CD4 T cells. Two levels of homogeneity were seen.
First, the LLV virus from plasma was predominately a single
variant. Second, approximately 50% of the induced virus was in
clusters, suggesting that half of the virus in resting CD4 T
cells is clonally expanded from a small number of cells.
The predominant LLV plasma viral sequence in patient 15
was found in only 2 of 21 outgrowth assays performed using
resting CD4 T cells. In order to detect the two infected
resting CD4 T cells containing the virus also found in LLV
plasma, approximately 50 million resting CD4 T cells were
cultured in 30 individual cultures. Therefore, in some patients,
it is possible that LLV viral species may originate from a minor
population of circulating CD4 T cells. Obviously, our finding
does not eliminate the possibility that replication-competent
HIV persists in cell populations other than resting CD4 T
cells for long periods of time despite ART, as suggested in
recent reports (6, 26). However, these reports similarly cannot
rule out the possibility that a minor population of resting
CD4 T cells containing virus identical to the LLV virus was
not assayed. Given the variability of the immune response and
FIG. 2. Phylogenetic analyses of patients 15 and 41. DNA sequences were aligned using CLUSTAL W (32). Phylogenetic trees were
constructed using the neighbor-joining method (27) implemented in CLUSTAL W with Kimura’s correction (17) by using Mega 4.0 (30).
Evolutionary distances were computed using the maximum-composite-likelihood method (31). (A) Neighbor-joining tree of 37 SGA-derived
full-length env sequences from resting CD4 T lymphocytes in patient 15. Black circles represent SGA-derived env sequences. (B) Neighbor-joining
tree of viruses derived from resting CD4 T cells and blood plasma in patient 15. Closed red circles, full-length SGA-derived env sequences from
plasma; open red circles, hypervariable V1-V2 SGA-derived sequences from plasma; closed black circles, full-length SGA-derived env sequences
derived from cell supernatants from first leukophoresis; open black circles, hypervariable V1 to V5 bulk PCR sequences from cell supernatants
from first leukophoresis; open black triangles, hypervariable V1-V5 bulk PCR sequences from all supernatants at second leukophoresis. (C) High-
lighter analysis of viruses derived from resting CD4 T cells and blood plasma from patient 41. The consensus sequence is included as the master.
Sequence names are indicated on the right. Each vertical tick represents a mismatch from the master as indicated in the figure. (D) Neighbor-
joining tree of V1 to V5 amplicons derived from resting CD4 T cells (black circles) in August 2009, blood plasma in January 2009 (open red
circles), and blood plasma in March 2010 (filled red circles). In each neighbor-joining tree, the percentages of replicate trees in which the associated
taxa clustered together in the bootstrap test (values of 60% with 500 replicates) are shown next to the branches. The trees are drawn to scale,
and the horizontal scale bar represents genetic distance (nucleotide subsititutions per site). All positions containing gaps and missing data were
eliminated from the data set. Strain HXB2 is included in the trees as an outgroup.
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differences in disease progression, persistent viremia could
originate from different sources in different patients. It will be
necessary to examine large numbers of CD4 T cells and other
potential viral reservoirs to characterize persistent reservoirs
of HIV.
Finally, our data indicate that viral diversification is effec-
tively halted after initiation of ART, given the identical/nearly
identical sequences observed from patient 41 (Fig. 2C and D).
An alternate scenario is that there is differential decay of
several populations of latently infected resting cells, and as
some populations express virus and are cleared, the remaining
population becomes more homogeneous over time. This pop-
ulation of “deeply latent” proviruses may also increase in pre-
dominance if indeed it is able to undergo homeostatic prolif-
eration (8). Analyses of longitudinal samples of resting cells
capable of releasing replication-competent virus from addi-
tional patients are needed to address this question further.
Nucleotide sequence accession numbers. JF421359 through
JF421448.
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